CASI - CASI Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

2.6900

+0.0800 (+3.07%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Double Moving Average Crossover

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	2.6100
Open	2.6400
Bid	2.3200 x 800
Ask	2.6800 x 1000
Day's Range	2.4700 - 2.7600
52 Week Range	1.1500 - 3.8200
Volume	285,567
Avg. Volume	253,204

Market Cap	271.461M
Beta (5Y Monthly)	0.82
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Simply Wall St.
Earnings Update: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Just Reported And Analysts Are Boosting Their Estimates
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) just released its latest first-quarter results and things are looking...
- New Forecasts: Here's What Analysts Think The Future Holds For Service Properties Trust (NASDAQ:SVC)
  Simply Wall St.
- Earnings Beat: Sapiens International Corporation N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
  Simply Wall St.
Simply Wall St.
Upgrade: Analysts Just Made A Notable Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders will have a reason to smile today, with the analysts making...
Zacks Small Cap Research
CASI: A Change in Strategy
By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the
Simply Wall St.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analysts Just Slashed This Year's Estimates
Market forces rained on the parade of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders today, when the analysts...
Simply Wall St.
Insider Buying: The CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Chairman & CEO Just Bought US$1.1m Worth Of Shares
Those following along with CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will no doubt be intrigued by the recent purchase...
Simply Wall St.
Did Changing Sentiment Drive CASI Pharmaceuticals's (NASDAQ:CASI) Share Price Down By 47%?
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
Benzinga
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
Zacks
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Benzinga
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
Simply Wall St.
What You Must Know About CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Beta Value
Anyone researching CASI Pharmaceuticals, Inc. (NASDAQ:CASI) might want to consider the historical volatility of the...
Simply Wall St.
Have Insiders Been Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St.
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops...
Zacks
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
GuruFocus.com
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $64,000 of Shares
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share. Continue reading...
Simply Wall St.
What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful...
Zacks Small Cap Research
CASI: CASI launches Evomela - first commercial product
On August 12,2019, CASI Pharmaceuticals (CASI) announced the commercial launch of Evomela, the only approved and commercially available form of melphalan available in China. This is the Company’s first commercialized product and we are encouraged to see that volatile trade tensions between the US and China do not appear to be hampering CASI’s progress towards establishing its footprint as a leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. Sharp price decreases often go hand-in-hand with inclusion on various “approved” drug lists in China, and we believe that CASI will opt for the lower-price/higher market share route in part to suppress potential competition.
GuruFocus.com
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $507,200 of Shares
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share. Continue reading...
Zacks
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.